BRAF and colorectal cancer: A phase Ib trial of encorafenib, cetuximab with or without alpelisib in 54 metastatic BRAF mutated colorectal cancer patients showed no significant difference in median PFS which was 3.7 months with the dual combination and 4.2 moths with the addition of alpelisib [39].